Richard young 2023

Richard Young

Managing Director and Principal Toxicologist

UKRT/ERT

Richard has >20 years’ experience in desk-based toxicology at bibra. He has an MSc in Applied Toxicology and is a RSB/BTS and European Registered Toxicologist (ERT). His skills include expert analysis of human health data. This can involve the pragmatic application of risk assessment methodology to mammalian toxicity data sets in order to derive robust conclusions on toxicological acceptability and health risks to exposed populations. In 2018, Richard became the Managing Director of bibra.

Richard has worked for clients from the food and beverage, food contact materials, consumer goods, agrochemical, biocidal, industrial chemical, pharmaceutical, electronic cigarette and cannabinoid sectors. For the past 15 years, he has been heavily involved in assisting companies comply with their REACH registration obligations, including supporting registrants respond to ECHA Evaluation decisions. Richard has played a key role in assisting e-cigarette and e-liquid manufacturers and importers with the toxicological assessments of their products, notably with their EU TPD and US FDA PMTA compliance obligations. Most recently he has been involved in the toxicological assessment of cannabinoids (notably CBD and THC) for a number of clients from a range of sectors (e.g. food, consumer products and pharmaceuticals).

In his spare time Richard can be found playing padel tennis and 5-a-side football (when his knees can cope), and running around and entertaining his two children.

Richard's case studies and blog posts

Save yourself the pain of last-minute reformulation with early ingredient screening

Blog articles

Developing a new consumer product? Maybe you’ve come up with the hottest new gadget or e-liquid flavour and are eager to get the product out to market as soon as possible. Prior to mass production, a safety evaluation is key. A preliminary screening assessment of the component ingredients during early development could save you a lot of time and money further down the line.

FDA memoranda: genotoxicity and carcinogenicity assessments of ENDS

Blog articles

As discussed in a previous blog post, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has issued several “scientific policy memoranda” that provide some great insights into the Agency’s evaluation process. In June 2024, the FDA made two new memos available that relate to the genotoxicity and carcinogenicity assessment of chemical constituents of Electronic Nicotine Delivery Systems (ENDS).

Evaluating the health risks posed by extractables and leachables from an ENDS device

Case study

In order to market their latest product in the United States, the client was intending to submit a Premarket Tobacco Product Application (PMTA) for a pod-based ENDS device.

Want to read more case studies and blog posts that Richard has been involved in? Click below to read more.

Contact us